Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study

BACKGROUND: Anti-programmed cell death protein-1 immunotherapy has been approved as a new treatment option for advanced hepatocellular carcinoma (HCC) based on the promising results of several studies. METHODS: This retrospective study included 71 patients with advanced HCC treated with anti-program...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Mei, Zhang, Yiruo, Wang, Hua, Liu, Pingping, Da, Jie, Du, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Current Technologies in Targeted Cancer Immunotherapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450682/
https://www.ncbi.nlm.nih.gov/pubmed/34525851
http://dx.doi.org/10.1177/15330338211038114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450682/
https://www.ncbi.nlm.nih.gov/pubmed/34525851
http://dx.doi.org/10.1177/15330338211038114

Ejemplares similares